Carisma, OrthoCellix Merger
This is a Orthocellix news story, published by Yahoo Finance, that relates primarily to NeoCart news.
Orthocellix news
For more Orthocellix news, you can click here:
more Orthocellix newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cartilage health. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest OrthoCellix news, chondrocytes news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
autologous cartilageTipRanks
•Health
Health
Carisma Therapeutics, OrthoCellix enter definitive merger agreement

69% Informative
Carisma Therapeutics (CARM) and OrthoCellix , a wholly-owned subsidiary of Ocugen (OCGN ) announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
The combined company will focus on the development of Orthocellix ’s NeoCart technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration -endorsed Phase 3 clinical trial for NeoCart .
VR Score
62
Informative language
60
Neutral language
50
Article tone
formal
Language
English
Language complexity
90
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links